Le Lézard
Classified in: Health, Science and technology
Subject: AWD

ProofPilot's Partnership with Moderna Nominated for Two Citeline Awards


NEW YORK, May 2, 2024 /PRNewswire/ -- ProofPilot, the industry's premier platform for patient & site automation, guidance, and seamless execution, announces today its nomination as a finalist for the second consecutive year at the Citeline Awards. This year, ProofPilot's partnership with Moderna received nominations in two categories: Clinical Partnership of the Year and Best Patient-facing Technology Initiative.

In the Clinical Partnership of the Year category, the nomination underscores ProofPilot's ability to work strategically with world-class life science partners and Moderna's commitment to innovation and collaboration.

Additionally, ProofPilot's nomination in the Best Patient-facing Technology Initiative category, again with Moderna, highlights its expertise in developing patient-centric technology solutions. "This nomination truly acknowledges the high impact of our work with the outstanding team at Moderna in clinical research. We appreciate everyone who has been a part of our journey so far. We're not done yet!" Chris Venezia, CEO of ProofPilot said.

ProofPilot's premiere offering Patient CoPilot, enhances patient engagement and adherence by fully automating and guiding patients through their study journey, ultimately improving study outcomes. Judges recognized ProofPilot's work and partnership with Moderna as one of the "best advances in improving patient data collection and/or the patient experience in clinical trials."

The Citeline Awards recognize excellence in clinical trial design, technological advancements, and results, as well as the outstanding achievements of individuals, departments, teams, or organizations. As a back-to-back finalist, ProofPilot continues to demonstrate its commitment to innovation and excellence in advancing clinical research.

About ProofPilot

Founded in 2014, ProofPilot enables flawless execution of research with the industry's only platform for clinical trial automation, guidance and knowledge management. The platform eliminates guesswork and reduces protocol deviations by orchestrating tasks and technology for patients and sites. ProofPilot delivers this capability through the Study CoPilot platform, with modules across study execution, from recruitment to conduct to post study. To learn more, visit https://www.proofpilot.com/.

Media Contact: Colleen yang, [email protected]

SOURCE ProofPilot


These press releases may also interest you

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...



News published on and distributed by: